All In Biotech

Drug Trial Radar · NCT05077462

A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers

An Open Label, Randomized, Single Dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate the Safety and Pharmacokinetics of AJU-C52H Compared to Coadministration of C52R1M With C52R2 in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Oct 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 17, 2021

Primary completion

Apr 30, 2022

Study completion Apr 30, 2022

Sponsor

Lead sponsor
AJU Pharm Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and pharmacokinetic characteristics of AJU-C52H in healthy adults

Conditions

  • Hypertension

Interventions

  • C52R1M Tab. and C52R2 Tab.Drug

    Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together

  • AJU-C52HDrug

    Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCt of AJU-C52Time frame: Pre-dose (0 hour), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
  2. Cmax of AJU-C52Time frame: Pre-dose (0 hour), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • H+ Yangji Hospital

    Seoul, Republic of South Korea, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.